title: Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations.
abstract: A familiar situation in migraine treatment is the patient with an initial positive response to prophylactic drug therapy who later experiences relapse. The goals of this paper are to provide a theoretical framework to help doctors think about this problem, to evaluate factors and response patterns that may be associated with different causes of relapse, and to suggest clinical strategies that may aid in its management. Six key explanations for loss of benefit from prophylactic therapy are: (1) pharmacokinetic, pharmacodynamic, and behavioral drug tolerance; (2) non-specific or placebo effects; (3) natural variability in disease activity; (4) disease progression; (5) inaccurate recall of treatment effects; and (6) drug delivery problems. Current options for patients who experience loss of benefit from prophylactic therapy include traditional techniques such as switching, re-trying, rotating, or combining drugs. Selected behavioral and environmental treatment techniques might also be useful. We describe a practical, structured approach to evaluation and management of relapse with migraine prophylaxis.
authors: John R. Graham Headache Center and Division of Headache and Pain, Department of Neurology, Brigham and Women's/Faulkner Hospitals, Boston, MA, USA. eloder@partners.org
authors: Elizabeth W
authors: EW
authors: Loder
authors: Paul
authors: P
authors: Rizzoli
mesh_terms: D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004361:Drug Tolerance; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000517:prevention & control*; D004364:Pharmaceutical Preparations; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D004364:Pharmaceutical Preparations